Beyond Bulls & Bears

Quick Thoughts: Biotech Progress in Addressing Coronavirus, but It Takes Time
Equity

Quick Thoughts: Biotech Progress in Addressing Coronavirus, but It Takes Time

With the coronavirus creating havoc across the globe, researchers are rushing to find better treatment options and a cure. Our Head of Equities, Stephen Dover, and Portfolio Manager Evan McCulloch outline a few of the efforts the medical and scientific communities are taking to combat the virus.

PODCAST: Health Care Sector Innovation and Insight
Equity

PODCAST: Health Care Sector Innovation and Insight

The biopharma industry has the potential to save lives with dramatic breakthroughs in new therapeutic drugs. In our latest “Talking Markets” podcast, our Head of Equities Stephen Dover speaks with analysts Steven Kornfeld and Krzysztof Musialik about health care innovations, particularly in the area of biopharma. They point out that in some cases, emerging markets are actually leading the way.

3 Reasons Why Investors Should Ignore Political Threats to Biotech
Equity

3 Reasons Why Investors Should Ignore Political Threats to Biotech

Given that the United States is considered a world leader in pharmaceutical innovation, we think it’s unlikely that politicians would want to impede the profit motivation of innovation and potentially severely impair the industry’s growth.